Board OKs AMT-130 Gene Therapy Trial to Enroll for High-dose Group

Board OKs AMT-130 Gene Therapy Trial to Enroll for High-dose Group

295411

Board OKs AMT-130 Gene Therapy Trial to Enroll for High-dose Group

A Phase 1/2 trial testing the safety and efficacy of AMT-130, uniQure’s experimental gene therapy for Huntington’s disease, can continue dosing after a positive recommendation from an independent board. The data safety monitoring board, which is overseeing the trial, reviewed safety data from the first group of 10 patients enrolled in the low-dose group (including those treated with placebo). The data spanned nine months (for two patients), six months (two patients), and 30 days (six patients). The…

You must be logged in to read/download the full post.